Skip to main content
SpringerLink
Log in

Myocardial kinetics of Tc-99m glucarate in low flow, hypoxia, and aglycemia

  • Published:
Journal of Nuclear Cardiology Aims and scope

Abstract

Background

Technetium-99m glucarate is a myocardial infarct-avid imaging agent. Recent conflicting and inconclusive reports have suggested that the agent may be taken up by ischemic but viable myocardium. The purposes of this study were (1) to determine conclusively whether there is Tc-99m glucarate uptake in ischemic viable myocardium and (2) to investigate the potential mechanisms for such uptake by studying components of ischemia, namely, low flow, hypoxia, and aglycemia.

Methods and Results

Rat hearts were isolated and perfused in a modified Langendorff preparation with a crytalloid perfusate. Tc-99m glucarate was studied in control (n = 6), low-flow (n = 5), hypoxic (n = 5), and aglycemic (n = 5) conditions. The experimental protocol consisted of 20-minute baseline (12 mL/min flow) and 20-minute treatment (low flow at 1 mL/min, hypoxia, or aglycemia), followed by tracer uptake (20 minute) and washout (20 minutes). Activity was monitored with a sodium iodide detector. The tracer was delivered continuously over a 20-minute uptake period. The injected dose was 150 μCi (5.6 MBq). Hemodynamics were monitored throughout. Triphenyltetrazolium chloride staining was used to assess myocardial viability. There was no evidence of myocardial necrosis. Low flow tended to delay tracer uptake compared with control for the first 10 minutes, but this did not reach statistical significance. Low flow increased end fractional retention significantly compared with control (mean ± SEM, 59.0% ± 0.9% peak vs 41.2% ± 1.4%, respectively; P < .05). Hypoxia resulted in a trend toward increased uptake; however, this was significant only at one early time point during the uptake phase. Retention in the hypoxia group was similar to control. Tc-99m glucarate uptake was significantly increased in aglycemia from 16 minutes to peak compared with control (1.36% ± 0.71% injected dose per gram vs 0.91% ± 0.37% injected dose per gram, respectively; P < .05). Aglycemia produced significantly higher end fractional retention compared with control (51.6% ± 1.8% peak vs 41.2% ± 1.4%, respectively; P < .05).

Conclusions

Tc-99m glucarate myocardial retention is increased in the setting of ischemia, even in the absence of necrosis. This increased retention is not due to hypoxia. Furthermore, the retention is only partially explained by tissue hypoglycemia. Thus low flow per se appears to have a role in this increased retention, probably as a result of delayed flow-dependent washout. (J Nucl Cardiol 2003;10:168-76.)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Khaw BA, Atsuko N, O’Donnell SM, Pak KY, Narula J. Avidity of technetium 99m glucarate for the necrotic myocardium: in vivo and in vitro assessment. J Nucl Cardiol 1997;4:283–90.

    Article  PubMed  CAS  Google Scholar 

  2. Narula J, Petrov A, Pak KY, Lister BC, Khaw BA. Very early nonivasive detection of acute experimental nonreperfused myocardial infarction with 99m-Tc-labeled glucarate. Circulation 1997; 95:1577–84.

    PubMed  CAS  Google Scholar 

  3. Yaoita H, Fischman AJ, Wilkinson R, et al. Distribution of deoxyglucose and technetium-99m-glucarate in the acutely ischemic myocardium. J Nucl Med 1993;34:1303–8.

    PubMed  CAS  Google Scholar 

  4. Ohtani H, Callahan RJ, Khaw BA, et al. Comparison of technetium- 99m-glucarate and thallium-201 for the identification of acute myocardial infarction in rats. J Nucl Med 1992;33:1988–93.

    PubMed  CAS  Google Scholar 

  5. Orlandi C, Crane PD, Edwards DS, et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl Med 1991;32:263–8.

    PubMed  CAS  Google Scholar 

  6. Beanlands RSB, Ruddy TD, Bielawski L, Johansen H. Differentiation of myocardial ischemia and necrosis by technetium 99m glucaric acid kinetics. J Nucl Cardiol 1997;4:274–82.

    Article  PubMed  CAS  Google Scholar 

  7. Mariani G, Villa G, Rossettin PF, et al. Detection of acute myocardial infarction by 99m-Tc-labeled d-glucaric acid imaging in patients with acute chest pain. J Nucl Med 1999;40:1832–9.

    PubMed  CAS  Google Scholar 

  8. Johnson LL, Schofield L, Mastronfrancesco P, et al. Technetium- 99m glucarate uptake in a swine model of limited flow plus increased demand. J Nucl Cardiol 2000;7:590–8.

    Article  PubMed  CAS  Google Scholar 

  9. Yaoita H, Uehara T, Brownell AL, et al. Localization of technetium- 99m-glucarate in zones of acute cerebral injury. J Nucl Med 1991;32:272–8.

    PubMed  CAS  Google Scholar 

  10. Ford WR, Clanachan AS, Hiley CR, Jugdutt BI. Angiotensin II reduces infarct size and has no effect on post-ischaemic contractile dysfunction in isolated rat hearts. Br J Pharmacol 2001;134:38–45.

    Article  PubMed  CAS  Google Scholar 

  11. Chopra P, Sabherwal U. Histochemical and fluorescent techniques for detection of early myocardial ischemia following experimental coronary artery occlusion: a comparative and quantitative study. Angiology 1988;39:132–40.

    Article  PubMed  CAS  Google Scholar 

  12. Rammohan R, Petrov A, Haider N, et al. Subnuclear localization of Tc-99m glucarate in necrotic myocardium [abstract]. J Nucl Med 1996;37:175P.

    Google Scholar 

  13. Khaw BA, Rammohan R. Tc-99m glucaric acid targets the nucleoproteins of acutely necrotic myocardium but cannot target myocardial cell death due to apoptosis [abstract]. Circulation 1999;100:I-310.

    Google Scholar 

  14. Khaw BA, DaSilva JS, Vora J, Boroujerdi M. Identification of adriamycin cardiotoxicity by two infarct avid agents: In-111 antimyosin and Tc-99m glucaric acid [abstract]. Circulation 1998;98:I-130.

    Google Scholar 

  15. Khaw BA, Petrov A, Vora JK, et al. Tc-99m glucarate is a marker of necrosis: it does not localize in adriamycin induced apoptotic myocardial injury [abstract]. J Nucl Med 1998;29:159P.

    Google Scholar 

  16. Bonte FJ, Parkey RW, Graham RT, Moore RT, Stokeley EM. A new method for radionuclide imaging of myocardial infarcts. Radiology 1974;110:473–4.

    PubMed  CAS  Google Scholar 

  17. Khaw BA, Gold HK, Yasuda T. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation 1986;74:501–8.

    PubMed  CAS  Google Scholar 

  18. Okada RD, Johnson G, Nguyen KN, et al. 99mTc-HL91, Effect of low flow and hypoxia on a new ischemia-avid myocardial imaging agent. Circulation 1997;95:1892–9.

    PubMed  CAS  Google Scholar 

  19. Ballinger JR, Cowan DS, Boxen I, Zhang ZM, Rauth AM. Effect of hypoxia on the accumulation of Tc-99m-glucarate and Tc-99mgluconate by Chinese hamster ovary cells in vivo. J Nucl Med 1993;34:242–5.

    PubMed  CAS  Google Scholar 

  20. Johnson G, Liu Z, Pak KY, Khaw B, Okada RD. Kinetics of 99mTc-glucarate in stunned, hibernating, and ischemic-reperfused myocardium with infarct. Circulation 2000;102:II-120.

    Google Scholar 

  21. Vural I, Narula J, Petrov A, Pak CKY, Khaw BA. Can Tc-99m glucarate also recognize diffuse myocardial necrosis? [abstract]. J Nucl Med 1995;36:47P.

    Google Scholar 

  22. Khaw BA, Petrov A, Narula J, Pak KY. Can the uptake ratios of Tc-99m-glucarate in acute myocardial infarction be affected by the glycemic state?. Biodistribution in fasted, non-fasted and insulin injection mice [abstract]. J Nucl Med 1999;40:186P.

    Google Scholar 

  23. Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. Coron Artery Dis 2001;40(Suppl 1):S3–7.

    Google Scholar 

  24. Young LH, Russell RR III, Yin R, et al. Regulation of myocardial glucose uptake and transport during ischemia and energetic stress. Am J Cardiol 1999;83:25H-30H.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Tulsa and the William K. Warren Medical Research Institute, University of Oklahoma, 6208 S Oswego Ave, 74136, Tulsa, OK, Oklahoma

    D. R. Okada, G. Johnson, Z. Liu, S. D. Hocherman & R. D. Okada

  2. Northeastern University, Boston, Massb

    B. A. Khaw

  3. Molecular Targeting Technologies, Inc, West Chester, Pa

    B. A. Khaw & K. Y. Pak

Authors
  1. D. R. Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. D. Hocherman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. A. Khaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Y. Pak
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. D. Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by grants from the American Heart Association, the William K. Warren Medical Research Institute, and the Anne and Henry Zarrow Foundation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okada, D.R., Johnson, G., Liu, Z. et al. Myocardial kinetics of Tc-99m glucarate in low flow, hypoxia, and aglycemia. J Nucl Cardiol 10, 168–176 (2003). https://doi.org/10.1067/mnc.2003.1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1067/mnc.2003.1

Key Words

Search

Navigation